Cancer trial pulled before it started: HPV drug study never enrolled a single patient
NCT ID NCT05363709
First seen Jan 17, 2026 · Last updated May 17, 2026 · Updated 15 times
Summary
This study was designed for people with HPV-positive oropharyngeal cancer who still had signs of the virus in their blood after finishing standard treatment. The goal was to see if an immunotherapy drug called BALSTILIMAB could clear the virus and improve long-term survival. However, the trial was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.